SGD Pharma, a global leader in pharmaceutical primary packaging solutions, is set to showcase its latest innovations at CPHI Worldwide 2024.
Held in Milan, Italy, from 8-10 October, the event will provide a platform for the company to highlight its commitment to sustainability and its ability to meet the evolving needs of the pharmaceutical industry.
One of the key highlights of SGD Pharma's exhibit will be the introduction of its siliconised moulded glass vials.
As the apparent only supplier worldwide offering such vials to pharmaceutical standards, SGD Pharma's siliconisation process provides enhanced protection for sensitive, aggressive, and viscous drug products.
The solution's internal coating helps to reduce interaction between the drug and the packaging, ensuring product integrity.
In addition to its siliconised vials, SGD Pharma will showcase its Sterinity EZ-fill vials, a ready-to-use (RTU) packaging solution designed to streamline the drug manufacturing process.
By offering RTU vials in both Type I and Type II moulded glass, SGD Pharma is providing customers with a comprehensive range of options to meet their specific needs.
Sustainability is a core value at SGD Pharma, and the company has made significant strides in reducing its environmental footprint.
Through initiatives such as renewable energy investments and process improvements, SGD Pharma is working towards a more sustainable future.
The company's commitment to green practices is further reflected in its participation in the UN Global Compact.
“At CPHI 2024 we are showcasing solutions developed with our pharma and veterinary customers’ needs in mind, aimed at enabling them to bring their drugs to market quickly and safely," said Olivier Rousseau, CEO of SGD Pharma.
"SGD Pharma’s renewable energy initiatives, including the upgrade of our furnace at Saint Quentin Lamotte (SQLM) in France and the installation of solar panels at our Vemula, India plant, underscore an overarching focus on decarbonisation with the company-wide goal to cut emissions recorded in 2020, by 35% by 2030 and by 65% by 2040."
Beyond its core offerings, SGD Pharma will also be presenting new caps for its Ensiemo syrup bottles, as well as an expanded range of LabServices for customers and partners.
These additional services aim to provide comprehensive support throughout the drug development and manufacturing process.
